



GOAL

Decrease % of admissions that do not receive racemic epinephrine after admission

ADMISSION CONSIDERATIONS

(does not substitute clinical judgment)

- Receives ≥ 3 racemic epinephrine or requires racemic epinephrine more frequently than **Q2 hours x 2 doses** in the ED **and/or**
- Persistent stridor at rest, respiratory distress, tachypnea **or**
- Inadequate hydration **or**
- Need for supplemental oxygen **or**
- Concern for alternative diagnosis


Does not exceed acute care floor care limitations:

- Floor can administer racemic epinephrine **Q1 hour x1 only**
- Floor cannot start heliox or positive pressure ventilation

DISCHARGE CRITERIA

- Receives ≥ 1 dexamethasone
- ≥ 2 hours since last racemic epinephrine treatment *(if received)*
- ≤ 2 racemic epinephrine within 4 hours
- Mild or improved croup symptoms (no or minimal stridor and suprasternal or intercostal retractions at rest)
- Able to talk and feed without difficulty
- No supplemental oxygen or hydration requirement

See more [evidence-based recommendations](#)





GOAL

Reduce length of stay: discharge patients without stridor at rest who meet discharge criteria **6 hours** after last racemic epinephrine

DISCHARGE CRITERIA

- ≥6 hours since last racemic epinephrine treatment
- Mild or improved croup symptoms (no or minimal stridor and suprasternal or intercostal retractions at rest)
- Stable off oxygen
- Able to talk and feed without difficulty
- No IV hydration requirement


GENERAL RECOMMENDATIONS

- Do not routinely order: imaging, antibiotics, viral testing, other laboratory testing
- Do not use cool mist or humidified air
- See more [evidence-based recommendations](#)

ENT REFERRAL & CONSULT

Consider ENT referral/consult if:

- recommend if age <1 year, consider if age <3 years
- history of intubation, history of inpatient ENT consult, prematurity, recurrent croup (>2 episodes in a year)
- concerns for foreign body and stridor in the absence of other upper respiratory infections





This guideline is developed based on the best available evidence and local expert consensus for elements of which evidence are inconclusive. Please refer recommendation table below for further details.

Croup CCG Overview

Background: Croup is a viral illness commonly associated with parainfluenza 1-3. It occurs primarily in late winter but can occur year-round. ^[1, 2]

Inclusion:

- All patients age 6 months to 6 years with primary diagnosis of croup

Exclusion:

- Direct admission from outside hospital or Lurie ED into PICU or OR
- Croup as secondary diagnosis in addition to co-diagnoses of pulmonary edema, bronchiolitis, asthma with status asthmaticus, asthma with acute exacerbation, vocal cord paralysis
- Complex chronic conditions, with the exception of mental retardation, epilepsy, chronic respiratory diseases, congenital anomalies for gastrointestinal, renal, and urologic system, chronic renal failure, chronic bladder diseases, and renal conditions requiring devices or technological support

Outcome measures:

- Proportion of patients who do not receive additional racemic epinephrine after admission from the ED
- Length of stay in inpatient and observation units (hour method)
- Admission rate

Process measures:

- Neck or chest XR use
- Respiratory Viral Panel use
- Antibiotic use
- Total nebulized racemic epinephrine given in the ED before admission
- Time of last racemic epinephrine given to discharge

Balancing measures:

- Length of stay (ED)
- Readmission rates within 3 days vs 7 days
- Return to ED within 3 days vs 7 days
- Critical Assessment Team (CAT) call

Complex chronic condition is defined as "any medical condition that can be reasonably expected to last at least 12 months (unless death intervenes) and to involve either several different organ systems or 1 organ system severely enough to require specialty pediatric care and probably some period of hospitalization in a tertiary care center". ^[3]

Recommendation Table (see final page for grading details)

Recommendation	Strength of recommendation	Quality of evidence
Give PO dexamethasone (0.6 mg/kg) instead of prednisolone to all patients with croup; give IM or IV if patient can't tolerate PO ^[4-12] . Consider repeat dose if no improvement is noted after 24 hours.	Strong, consensus for repeat dose	Low to moderate
Give inhaled racemic epinephrine for patients with moderate to severe croup symptoms ^[9, 12, 13]	Strong	High
Observe patient for ≥2 hours after last racemic epinephrine administration in the ED ^[12, 14]	Strong	Moderate
Do not admit all patients requiring multidose epinephrine ^[15-17] . Consider symptoms besides absolute number of racemic epinephrine received ^[15, 17-21]	Strong, consensus	Low to moderate
Discharge patient admitted with croup ≥6 hours after the last dose of racemic epinephrine ^[18]	Strong, consensus	Moderate
Emphasize follow up visits within the first week after discharge ^[22]	Weak	Moderate
Do not use humidified air or cool mist ^[9, 11, 12, 23, 24]	Strong	Low to moderate



Do not routinely use heliox ^[9, 11, 25]	Strong	Low to moderate
Suggest scoping if meet criteria below ^[20, 26-28] . Severe cases do not need ENT consult unless airway needs to be secured. <ul style="list-style-type: none"> - recommend if age <1 year, consider if < 3 years - history of intubation - history of inpatient ENT consult - prematurity, recurrent croup (>2 episodes in a year) - concerns like foreign body and stridor in the absence of URI and symptoms do not improve after several days of treatment 	Strong, consensus	Low to moderate
Evaluate for alternative diagnoses for patients who do not follow typical course ^[29] . Common diagnoses: <ul style="list-style-type: none"> - foreign body - subglottic stenosis - subglottic hemangioma 	Strong, consensus	Low
Do not routinely order imaging ^[30]	Consensus	Low
Do not routinely order laboratory testing (respiratory viral panel) ^[1, 2]	Consensus	

Literature Review Contributors

Clinical leads:

Ann-Marie Tantoco, MD
Matthew Shapiro, MD
Virginia Hsu, MD

Improvement consultants:


Kelly Heyrman, RN
Kim Kato, RN

Librarian:

Andrea Fawcett

Key members:


Dana Evans, RT
Elizabeth Powell, MD
Emma Anselin, MD
Erin Harvey, MD
Giselle Rodriguez, MD
Jennifer Lavin, MD
Jessica Ribaud, RN
Karina Cienas, RT
Kavita Alford, MD
Kristen Mikula, APN
Kristine Cieslak, MD
Madeline Field, MD
Margaret Hoffmeister, Rph
Michal Graca, RT
Nawal Momani, MD
Nicholas Zessis, MD
Sarah Carlquist, RN
Sriram Ramgopal, MD
Sukhraj Mudahar, Rph





1. Hsieh, Y.J., et al., *Hospitalized pediatric parainfluenza virus infections in a medical center*. Journal of Microbiology, Immunology & Infection, 2010. **43**(5): p. 360-5.
2. Frost, H.M., C.C. Robinson, and S.R. Dominguez, *Epidemiology and clinical presentation of parainfluenza type 4 in children: a 3-year comparative study to parainfluenza types 1-3*. Journal of Infectious Diseases, 2014. **209**(5): p. 695-702.
3. Feudtner, C., et al., *Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation*. BMC Pediatrics, 2014. **14**(1).
4. Aljebab, F., et al., *Observational study on the palatability and tolerability of oral prednisolone and oral dexamethasone in children in Saudi Arabia and the UK*. Arch Dis Child, 2018. **103**(1): p. 83-88.
5. Dobrovoljac, M. and G.C. Geelhoed, *How fast does oral dexamethasone work in mild to moderately severe croup? A randomized double-blinded clinical trial*. Emerg Med Australas, 2012. **24**(1): p. 79-85.
6. Elliott, A.C. and G.R. Williamson, *A Systematic Review and Comprehensive Critical Analysis Examining the Use of Prednisolone for the Treatment of Mild to Moderate Croup*. Open Nurs J, 2017. **11**: p. 241-261.
7. Garbutt, J.M., et al., *The comparative effectiveness of prednisolone and dexamethasone for children with croup: a community-based randomized trial*. Clin Pediatr (Phila), 2013. **52**(11): p. 1014-21.
8. Gates, A., D.W. Johnson, and T.P. Klassen, *Glucocorticoids for Croup in Children*. JAMA Pediatrics, 2019. **173**(6): p. 595-596.
9. Johnson, D.W., *Croup*. Clinical Evidence, 2014. **29**: p. 29.
10. Parker, C.M. and M.N. Cooper, *Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial*. Pediatrics, 2019. **144**(3).
11. Petrocheilou, A., et al., *Viral croup: diagnosis and a treatment algorithm*. Pediatr Pulmonol, 2014. **49**(5): p. 421-9.
12. Pitluk, J.D., H. Uman, and S. Safranek, *Clinical inquiries. What's best for croup?* J Fam Pract, 2011. **60**(11): p. 680-1.
13. Bjornson, C., et al., *Nebulized epinephrine for croup in children*. Cochrane Database Syst Rev, 2013(10): p. Cd006619.
14. Maalouli, W.M. and J.S. Hodges, *Croup Admissions: Can We Shrink the Elephant in the Room?* Pediatr Emerg Care, 2019.
15. Asmundsson, A.S., et al., *Hospital Course of Croup After Emergency Department Management*. Hosp Pediatr, 2019. **9**(5): p. 326-332.
16. Bagwell, T., et al., *Management of Croup in the Emergency Department: The Role of Multidose Nebulized Epinephrine*. Pediatr Emerg Care, 2017.
17. Elder, A.E. and A. Rao, *Management and outcomes of patients presenting to the emergency department with croup: Can we identify which patients can safely be discharged from the emergency department?* J Paediatr Child Health, 2019. **55**(11): p. 1323-1328.
18. Chiang, E., et al., *Inpatient use of racemic epinephrine for children admitted with croup*. World J Pediatr, 2019. **15**(6): p. 586-594.
19. Hester, G., et al., *Rate of Airway Intervention for Croup at a Tertiary Children's Hospital 2015-2016*. J Emerg Med, 2019. **57**(3): p. 314-321.
20. Rudinsky, S.L., et al., *Inpatient Treatment after Multi-Dose Racemic Epinephrine for Croup in the Emergency Department*. J Emerg Med, 2015. **49**(4): p. 408-14.
21. Yang, W.C., et al., *Westley score and clinical factors in predicting the outcome of croup in the pediatric emergency department*. Pediatr Pulmonol, 2017. **52**(10): p. 1329-1334.
22. Bucholz, E.M., et al., *Timing and Causes of Common Pediatric Readmissions*. J Pediatr, 2018. **200**: p. 240-248.e1.
23. Moore, M. and P. Little, *Humidified air inhalation for treating croup*. Cochrane Database Syst Rev, 2006(3): p. CD002870.
24. Moraa, I., et al., *Heliox for croup in children*. Cochrane Database Syst Rev, 2018. **10**: p. Cd006822.
25. Kline-Krammes, S., et al., *Heliox in children with croup: a strategy to hasten improvement*. Air Med J, 2012. **31**(3): p. 131-7.
26. Hiebert, J.C., Y.D. Zhao, and E.B. Willis, *Bronchoscopy findings in recurrent croup: A systematic review and meta-analysis*. Int J Pediatr Otorhinolaryngol, 2016. **90**: p. 86-90.
27. Jabbour, N., et al., *Incidence of operative endoscopy findings in recurrent croup*. Otolaryngol Head Neck Surg, 2011. **144**(4): p. 596-601.
28. Smith, D.K., A.J. McDermott, and J.F. Sullivan, *Croup: Diagnosis and Management*. Am Fam Physician, 2018. **97**(9): p. 575-580.
29. Cooper, T., et al., *Atypical croup: association with airway lesions, atopy, and esophagitis*. Otolaryngol Head Neck Surg, 2012. **147**(2): p. 209-14.
30. Yang, W.C., et al., *Initial radiographic tracheal ratio in predicting clinical outcomes in croup in children*. Sci Rep, 2019. **9**(1): p. 17893.

Rating the Quality of Evidence using GRADE



Design limitations	<ul style="list-style-type: none"> Lack of blinding - members involved in study are aware of which arm the patient is allocated Lack of allocation concealment – enrolled patients are aware of which group the next enrolled patient will be allocated Large losses to follow up Incorrect analysis of Intention to treat (ITT) Stopped early for benefit Selective reporting of measured outcomes (e.g. no effect outcomes) – incomplete or absent reporting of some outcomes and not others on the basis of the results
Inconsistency of results	<ul style="list-style-type: none"> Wide variation of treatment effect across studies Population varied Interventions varied Outcomes varied
Indirectness of evidence	<ul style="list-style-type: none"> Head-to-head comparison in correct population Indirect comparisons Different populations – indirectness in population Different interventions – interventions delivered differently in different settings Different outcomes measured – time differences, use of surrogate outcomes in place of patient important outcomes Comparisons not applicable to questions/ outcome
Imprecision	<ul style="list-style-type: none"> Sample size lower than calculated optimal size Total # of events <300 95% CI includes negligible effect and appreciable benefit of harm Wide confidence interval Confidence interval not reported
Publication bias	<ul style="list-style-type: none"> Studies with 'negative' findings remain unpublished
Large consistent effect	<ul style="list-style-type: none"> Effect cannot be accounted for by bias common to the study; usually when relative risk are > 5 or < 2
Dose response	<ul style="list-style-type: none"> when the result is proportional to the degree of exposure
Confounding only reduce size of effect	<ul style="list-style-type: none"> when all possible confounders would only diminish the observed effect. It is likely that the actual effect is larger than the data suggests

What does our rating mean to our readers?	
High	We are very confident that the effect in the study reflects the actual effect
Moderate	We are quite confident that the effect in the study is close to the true effect, but it is also possible it is substantially different
Low	The true effect may differ significantly from the estimate
Very Low	The true effect is likely to be substantially different from the estimated effect

References

- Goldet, G., & Howick, J. (2013) Understanding GRADE: an introduction. *Journal of Evidence-Based Medicine*, 6(1): 50-54. <https://doi.org/10.1111/jebm.12018>
- Schünemann, H., Brożek, J., Guyatt, G., & Oxman, A. (2013). *GRADE Handbook*. Retrieved from: <https://gdt.gradepro.org/app/handbook/handbook.html#h.svwngs6pm0f2>